Professor, Medicine, University of Maryland School of Medicine
Oncology
Dr. Edward A. Sausville, MD
|
|
Give Review
Edward A. Sausville practices Oncology. He graduated from Albert Einstein College of Medicine of Yeshiva University. He received 2 awards: "CMS Meaningful Use Stage 1 Certification" and "Whos Who in Medicine and Healthcare". Edward Sausville is a published doctor as well. He has 94 publications published. The latest was: Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms. He is registered with Medicare and accepts Medicare payments.
Publications
- Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.
- Major clinical response to nivolumab in relapsed/refractory Hodgkin Lymphoma after allogeneic stem cell transplantation.
- First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid Tumors.
- Disparities in black and white patients with multiple Myeloma referred for autologous hematopoietic transplantation: A single center study.
- Autophagy modulation: a target for Cancer treatment development.
- A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.
- Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid Tumors.
- Ten-day decitabine as initial therapy for newly diagnosed patients with Acute myeloid leukemia unfit for intensive chemotherapy.
- Asparaginase in the treatment of non-ALL hematologic malignancies.
- Schistocytes, echinocytes, iron deficiency Anemia, and thrombocytopenia - hematologic manifestations of splenic angiosarcoma.
- PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinu...
- Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in Acute leukemias.
- Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2.
- Unbalanced 11;18 translocation in an Acute erythroid leukemia after radioactive iodine therapy.
- Phase I study of UCN-01 and perifosine in patients with relapsed and refractory Acute leukemias and high-risk myelodysplastic syndrome.
- Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors.
- Promises from Trametinib in RAF Active Tumors.
- Subdural hematomas in patients with Philadelphia chromosome-positive Acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathe...
- Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications.
- Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
- Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in Cancer patients.
- Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate Cancer drug delivery.
- Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate Cancer therapy.
- Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of Acute leukemias.
- Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell Lymphoma combination therapy.
- A mechanistic perspective of monoclonal antibodies in Cancer therapy beyond target-related effects.
- Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed Acute leukemias.
- Inhibition of mitochondrial respiration as a source of adapHostin-induced reactive oxygen species and cytotoxicity.
- Molecular mechanism of adaphostin-mediated G1 arrest in prostate Cancer (PC-3) cells: signaling events mediated by hepatocyte growth factor receptor, c-Met, and p38 MA...
- Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with Cancer.
- Respecting Cancer drug transportability: a basis for successful lead selection.
- The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's Sarcoma-associated herpesvirus G protein-coupled receptor.
- Contributions of human tumor xenografts to antiCancer drug development.
- Differential gene expression as a potential classifier of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole-sensitive and -insensitive cell lines.
- Ligand-directed surface profiling of human Cancer cells with combinatorial peptide libraries.
- Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and...
- Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
- Preclinical modeling of combination treatments: fantasy or requirement?
- Benzodithiophenes induce differentiation and apoptosis in human Leukemia cells.
- Transcriptional profiling identifies altered intracellular labile iron homeostasis as a contributing factor to the toxicity of adapHostin: decreased vascular endotheli...
- Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or Lymphoma.
- Making bad cells go good: the promise of epigenetic therapy.
- Homology model of the CDK1/cyclin B complex.
- Review of UCN-01 development: a lesson in the importance of clinical pharmacology.
- Indifferently pursued or unowned drugs: who should lead where companies do not tread?
- AdapHostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine.
- Histone deacetylase inhibitor pharmacodynamic Analysis by multiparameter flow cytometry.
- Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human Cancer cells.
- Atiprimod is an inhibitor of Cancer cell proliferation and angiogenesis.
- In vivo models for experimental therapeutics relevant to human Cancer.
- 7-hydroxystaurosporine (UCN-01) inhibition of Akt Thr308 but not Ser473 phosphorylation: a basis for decreased insulin-stimulated glucose transport.
- Components of the cell death machine and drug sensitivity of the National Cancer Institute Cell Line Panel.
- Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine.
- SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular ...
- SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy ...
- Versipelostatin: unfolding an unsweetened death.
- In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against proState (PC-3) and lung (A549) epithelial adenocarcinoma cell lines.
- Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.
- Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01.
- Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 Breast tumor cells.
- Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry.
- Genes in the service of therapeutic index: progress for virus-directed enzyme prodrug therapy.
- Akt plays a central role in Sarcomagenesis induced by Kaposi's Sarcoma herpesvirus-encoded G protein-coupled receptor.
- Aurora kinases dawn as Cancer drug targets.
- Gene expression correlating with response to paclitaxel in ovarian carcinoma xenoGrafts.
- Identification of small molecule inhibitors of anthrax lethal factor.
- Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human Leukemia cells.
- Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: a potential surrogate marker for patient sensitivity.
- Meeting report on the Ninth Conference on Cancer Therapy with Antibodies and Immunoconjugates.
- Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.
- Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity.
- Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.
- A high-throughput screen for identification of molecular mimics of Smac/DIABLO utilizing a fluorescence polarization assay.
- Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways.
- Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling.
- Preclinical models for defining efficacy of drug combinations: mapping the road to the clinic.
- "Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies.
- Is another bcr-abl inhibitor needed for chronic myelogenous Leukemia?
- Genotoxic profiling of MCF-7 breast Cancer cell line elucidates gene expression modifications underlying toxicity of the antiCancer drug 2-(4-amino-3-methylphenyl)-5-f...
- Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6.
- Signal transduction--directed Cancer treatments.
- Drug discovery targeting Chk1 and Chk2 kinases.
- Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
- Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
- Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.
- Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
- Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent ...
- Establishing connections between microarray expression data and chemotherapeutic Cancer pharmacology.
- Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breas...
- Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities.
- Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles.
- Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous Leukemia cells in vitro.
- Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast Cancer cells to antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole.
Schools
Albert Einstein College of Medicine of Yeshiva University
Brigham Womens Hospital
National Canc Institute
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Whos Who in Medicine and Healthcare
Education
-
National Institutes of Health Clinical Center -
Brigham and Women's Hospital -
Albert Einstein College of Medicine of Yeshiva University
Hospital
-
University of Maryland Baltimore Washington Medical Center -
University of Maryland Medical Center
Drug Facts
| NPI NUMBER | 1528020393 | |
| NPPES Provider LastName | SAUSVILLE | |
| NPPES Provider FirstName | EDWARD | |
| NPPES Provider ZIPCode | 212011544 | |
| NPPES Provider State | MD | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 143.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 18.0 | |
| Percent Opioid Claims | 12.59 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1528020393 |
| Last Name Of The Provider | SAUSVILLE |
| First Name Of The Provider | EDWARD |
| View All |
Similar Doctors
|
|
Dr. Hayden G. Braine, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Margit N. Horiba, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Evan J. Lipson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher A. Klebanoff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Martin J. Edelman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Curt I. Civin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arlene A. Forastiere, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Louise B. Grochow, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cesar A. Santa-Maria, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher G. Kanakry, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard Humphrey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. F J. Bolanos Meade, MD
This Doctor is OpenDoctor Recommended.
|